Clinical Trial

Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.
Protocol Amendment History 1 change
notable Enrollment increased: 44 -> 49 participants 2026-07-15
Trial Details
NCT Number NCT07472933
Lead Sponsor West China Hospital
Conditions Cancer of Biliary Duct
Enrollment 49 participants
Start Date 2026-08-01
Primary Completion 2028-02-29 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-14